IRIDEX Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $51.6M+6.0% YoYTTM through 4 Jul 2026
Net Income -$3.5MTTM through 4 Jul 2026
Free Cash Flow -$2MTTM through 4 Jul 2026
Margins
| Current | |
|---|---|
| Gross Margin | 36.5% |
| EBITDA Margin | -4.5% |
| Operating Margin | -4.9% |
| Net Margin | -6.9% |
Returns
-90.2%ROE
-15.2%ROA
Balance Sheet Health
Debt / Equity0.81x
Current Ratio2.10x
Net Debt-$2Mnet cash position
Cash & Equivalents$4.7M
Quality Metrics
Altman Z-Score-2.53
Piotroski F-Score3 / 9
FCF Margin-3.9%
Rule of 40-1.1
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2026: $52.7M
Diluted EPS-$0.20TTMFY2026: $-0.26
Dividend
No dividend
Capital Allocation
R&D Spend$3.8M
Capex Intensity0.5%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Retina | $30.3M | +9.0% | |
| Glaucoma (Cyclo G6 product family) | $13.8M | +8.7% | |
| Other | $8.6M | +6.2% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.